DXR צמיחת רווח נקי למניה השנה Daxor Corp.

Daxor Corporation generates revenue through the sale of BVA-100 systems for blood volume monitoring. The annual relative change in EPS illustrates profit dynamics, where the -321.20 mark serves as the current indicator. The issuer collaborates with cardiology centers, implementing solutions for heart failure therapy. Patent protection and FDA certification create a significant barrier to entry for new players in this niche.

This indicator measures the year-over-year dynamics of net earnings per share, determining the business scaling rate. By analyzing the annual EPS change, an investor can identify the acceleration or deceleration vector of profits. The metric is calculated as the percentage deviation of the current earnings value from the same period last year. For Daxor Corporation (DXR), such volatility is smoothed out by recurring payments for consumables. Stable demand for unique blood measurement systems ensures predictable growth of this fundamental parameter.